Fulvicin P/g 165
Drug - Fulvicin P/g 165
The trade name of the product as shown on the labeling.
Dosage -
TABLET; ORAL
The product dosage form and route separated by a semi-colon.
Active Ingredient(s) -
Griseofulvin, Ultramicrocrystalline
Multiple ingredients are in alphabetical order.
Strength -
165MG
The potency of the active ingredient(s), Griseofulvin, Ultramicrocrystalline. May repeat for multiple part products.
Applicant -
SCHERING
The firm name holding legal responsibility for Fulvicin P/g 165. The firm name is condensed to a maximum twenty character unique string.
New Drug Application (NDA) Number -
061996
The FDA assigned number to Fulvicin P/g 165. Format is nnnnnn.
Product Number -
003
The FDA assigned number to identify Fulvicin P/g 165. Each strength is a separate product. May repeat for multiple part products. Format is nnn.
Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.
Approval Date -
Apr 6, 1982
The date Fulvicin P/g 165 was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".
Reference Listed Drug (RLD) -
No
The pioneer or innovator of Fulvicin P/g 165. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.
Type -
DISCN
The group or category of approved drugs Fulvicin P/g 165 is in. Format is RX, OTC, DISCN.
Applicant Full Name -
Schering Corp Sub Schering Plough Corp
The full name of the firm holding legal responsibility for the new application of Fulvicin P/g 165.
Fulvicin P/g 165
|